638352-78-0

Usage

InChI:InChI=1/C12H14N2O/c1-9-4-5-10(2)14(9)12-7-6-11(15-3)8-13-12/h4-8H,1-3H3

Upstream product

• 110-13-4 2,5-hexanedione 
• 228710-82-5 5-bromo-2-(2,5-dimethyl-pyrrol-1-yl)-pyridine 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 477889-91-1 1-(5-iodopyridin-2-yl)-2,5-dimethyl-1H-pyrrole 

Downstream Products

• 1936529-65-5 3-(2-chloro-6-methylphenyl)-7-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one 
• 139585-48-1 2-chloro-5-methoxypyridine 
• 10167-97-2 2-amino-5-methoxypyridine 

Relevant academic research and scientific papers

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

Synthesis of 2-amino-5-hydroxypyridine via demethoxylation

A convenient and efficient four-step synthesis of 2-amino-5-hydroxypyridine can be achieved by protective reaction of 2-amino-5-bromopyridine in the presence of 2,5-hexanedione to yield 5-bromo-2-(2,5-dimethyl-1H-pyrrol-1yl)pyridine, methoxylation with sodium methylate to give 5-methoxy-2-(2,5-dimethyl-1H-pyrrol-1yl)pyridine, deprotective reaction with hydroxylamine hydrochloride to produce 2-amino-5-methoxypyridine and demethylation with 95 % H2SO4 to afford the title compound in an overall yield of 45 %.

HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES

HIV inhibitory compounds of formula (I) salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R1 is halo, cyano, nitro, C1-6alkyl, polyhaloC1-6alkyl, -C1-6alkyl-OR4, -C(=O)-R5, -C(=O)-OR4, -C(=O)-NR6R7, -OR4, -O-C(=O)-C1-6alkyl, -O-C1-6alkyl-OR4, -O-C1-6alkyl-NR6R7, -O-C1-6alkyl-O-C(=O)-C1-6Alkyl, -O-C1-6alkyl-C(=O)-OR4, -O-C1-6alkyl-C(=O)-NR6R7, -NR6R7, -NR8-C(=O)-R5, -NR8-C(=O)-OR4, -NR8-C(=O)-NR6R7, -NR8-C(=O)-C1-6lkyl-C(=O)-OR4, -NR8-C1-6alkyl-OR4, -NR8-C1-6alkyl-NR6R7, -NR8-C1-6alkyl-imidazo lyl, -NR8-SO2R9, -N=CH-NR6R7, -NH-C(=NH)-NH2, -SO2NR6R7, and -O-PO(OR8)2; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R2 is C1-6alkyl, polyhaloC1-6alkyl, halo, cyano, -COOR4, -OR4, and -NR6R7; R3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.

Synthesis of Differently Disubstituted 2,2′-Bipyridines by a Modified Negishi Cross-Coupling Reaction

A general practical approach to a number of differently disubstituted 2,2′-bipyridines from substituted 2-bromo- and 2-chloropyridines by application of modified Negishi cross-coupling conditions has been developed. These 2,2′-bipyridines carry versatile functional groups that can be elaborated further, as demonstrated for some examples. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.